Serina Therapeutics to Present at 38th Annual Roth Conference

Biotech company to showcase its proprietary POZ Platform technology for drug optimization.

Mar. 24, 2026 at 10:39am

Got story updates? Submit your updates here. ›

Serina Therapeutics, a clinical-stage biotechnology company, announced that its CEO Steve Ledger will present at the 38th Annual Roth Conference in Dana Point, California on March 24, 2026. Serina's proprietary POZ Platform technology aims to improve the efficacy and safety profile of various drug modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates.

Why it matters

Serina's POZ Platform has the potential to enhance the therapeutic potential of existing drugs by improving their pharmacokinetic profiles, which can help address issues like toxicity, side effects, and short half-life. This could lead to more effective treatments for neurological diseases and other indications.

The details

Serina's presentation at the Roth Conference will provide an overview of the company's POZ Platform technology and its pipeline of drug candidates, including SER-252, an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation for Parkinson's disease. The live webcast of the fireside chat will be accessible to registered attendees, and an archived replay will be available for 90 days following the event.

  • Serina Therapeutics will present at the 38th Annual Roth Conference on March 24, 2026 at 11:30 a.m. PST.
  • The live webcast of the presentation will be accessible to registered attendees.
  • An archived replay of the presentation will be available on-demand for 90 days following the event.

The players

Serina Therapeutics, Inc.

A clinical-stage biotechnology company developing a pipeline of drug product candidates using its proprietary POZ Platform technology to treat neurological diseases and other indications.

Steve Ledger

Chief Executive Officer of Serina Therapeutics.

Pfizer, Inc.

Serina has a non-exclusive license agreement with Pfizer to use its POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.

SER-252 (POZ-apomorphine)

An investigational apomorphine therapy developed by Serina using its POZ platform and designed to provide continuous dopaminergic stimulation for Parkinson's disease.

HudsonAlpha Institute of Biotechnology

The campus where Serina Therapeutics is headquartered in Huntsville, Alabama.

Got photos? Submit your photos here. ›

What’s next

Serina plans to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

The takeaway

Serina's proprietary POZ Platform technology has the potential to improve the efficacy and safety of various drug modalities, which could lead to more effective treatments for neurological diseases and other indications. The company's presentation at the Roth Conference will showcase this innovative technology and its pipeline of drug candidates.